Rofecoxib

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Neurology

• Publication date

  2004-01-13

• Fields of study

  Medicine

• Identifiers
  DOI 10.1212/WNL.62.1.66PMID 14718699
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone).

  2002cited by this paper
• In-vivo measurement of activated microglia in dementia.

  2001cited by this paper
• Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease.

  2001cited by this paper
• The gastrointestinal safety profile of rofecoxib, a highly selective inhibitor of cyclooxygenase‐2, in humans

  2001cited by this paper
• A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity

  2001cited by this paper
• COX-2 inhibitors. Are they nonsteroidal anti-inflammatory drugs with a better safety profile?

  2001cited by this paper
• Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.

  2000cited by this paper
• A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis. Rofecoxib/Ibuprofen Comparator Study Group.

  2000cited by this paper
• Fear recognition deficits after focal brain damage

  2000cited by this paper
• A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer’s disease

  1999cited by this paper
• COX-2 inhibitors.

  1999cited by this paper
• Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs.

  1999cited by this paper
• Cyclooxygenase‐2 inhibition by rofecoxib reverses naturally occurring fever in humans

  1999cited by this paper
• The safety profile, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritis. Phase II Rofecoxib Rheumatoid Arthritis Study Group.

  1999cited by this paper
• Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis.

  1999cited by this paper
• The Physiology and Pharmacology of Melatonin in Humans

  1998cited by this paper
• Relationship of Disease Severity to Decline on Specific Cognitive and Functional Measures in Alzheimer Disease

  1998cited by this paper
• A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease

  1998cited by this paper
• Using the general linear mixed model to analyse unbalanced repeated measures and longitudinal data.

  1997cited by this paper
• An Inventory to Assess Activities of Daily Living for Clinical Trials in Alzheimer's Disease

  1997cited by this paper
• Performance of the Dementia Severity Rating Scale: A Caregiver Questionnaire for Rating Severity in Alzheimer Disease

  1996cited by this paper
• A 1-year multicenter placebo-controlled study of acetyl-L-carnitine in patients with Alzheimer's disease

  1996cited by this paper
• Observations and Suggestions on Antidementia Drug Development

  1996cited by this paper
• Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease

  1996cited by this paper
• The Clinician Interview‐ Based Impression (CIBI)

  1994cited by this paper
• The Clinical Dementia Rating (CDR)

  1993cited by this paper
• Clinical trial of indomethacin in Alzheimer's disease

  1993cited by this paper
• Clinical diagnosis of Alzheimer's disease

  1984cited by this paper
• A new rating scale for Alzheimer's disease.

  1984cited by this paper
• “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician

  1975cited by this paper

• Targeting Inflammation in Alzheimer’s Disease: Insights Into Pathophysiology and Therapeutic Avenues-A Comprehensive Review

  2025cites this paper
• A review: From old drugs to new solutions: The role of repositioning in alzheimer's disease treatment.

  2025cites this paper
• Influence of Ibuprofen on glycerophospholipids and sphingolipids in context of Alzheimer´s Disease.

  2025cites this paper
• Role of Nonsteroidal Anti-Inflammatory Drugs as a Protective Factor in Alzheimer's Disease: A Systematic Review and Meta-Analysis.

  2024cites this paper
• The effect of probiotics on select cognitive domains in mild cognitive impairment and Alzheimer's disease: A systematic review and meta-analysis

  2024cites this paper
• Selective COX-2 Inhibitors as Neuroprotective Agents in Traumatic Brain Injury

  2024cites this paper
• Img2Side: A Transfer Learning Based Model for Predicting Drug Side Effects Using 2D Chemical Structural Images

  2024cites this paper
• Genetic model of selective COX2 inhibition improve learning and memory ability and brain pathological changes in 5xFAD mouse.

  2023cites this paper
• Antibody-Mediated Clearance of Brain Amyloid-β: Mechanisms of Action, Effects of Natural and Monoclonal Anti-Aβ Antibodies, and Downstream Effects

  2023cites this paper
• Peripheral inflammation is a potential etiological factor in Alzheimer’s disease

  2023cites this paper
• Aspirin Therapy, Cognitive Impairment, and Dementia—A Review

  2023cites this paper
• Microglia as a cellular target of diclofenac therapy in Alzheimer’s disease

  2023cites this paper
• Non-steroidal Anti-Inflammatory Drugs as protective Factor in Alzheimer's Diseases: a Systematic Review and Meta-Analysis Protocol (Preprint)

  2022cites this paper
• A Pathophysiological Intersection of Diabetes and Alzheimer’s Disease

  2022cites this paper
• Neuroinflammation and oxidative stress in Alzheimer's disease; Can nutraceuticals and functional foods come to the rescue?

  2022cites this paper
• Insights into the Pathophysiology of Alzheimer’s Disease and Potential Therapeutic Targets: A Current Perspective

  2022cites this paper
• A tough trek in the development of an anti-amyloid therapy for Alzheimer's disease: Do we see hope in the distance?

  2022cites this paper
• Peripheral inflammation and neurodegeneration; a potential for therapeutic intervention in Alzheimer’s disease (AD), Parkinson’s disease (PD) and amyotrophic lateral sclerosis (ALS)

  2022cites this paper
• Potentiation of microglial endocannabinoid signaling alleviates neuroinflammation in Alzheimer's disease.

  2021cites this paper
• Involvement and relationship of bacterial lipopolysaccharides and cyclooxygenases levels in Alzheimer's Disease and Mild Cognitive Impairment patients.

  2021cites this paper
• Modulation of neuroinflammation by low-dose radiation therapy in an animal model of Alzheimer's disease.

  2021cites this paper
• Critical Appraisal of Amyloid Lowering Agents in AD

  2021cites this paper
• Novel Applications of NSAIDs: Insight and Future Perspectives in Cardiovascular, Neurodegenerative, Diabetes and Cancer Disease Therapy

  2021cites this paper
• Targeting innate immunity to protect and cure Alzheimer’s disease: opportunities and pitfalls

  2021cites this paper
• Neuroinflammation in neurological disorders: pharmacotherapeutic targets from bench to bedside

  2021cites this paper
• Design, synthesis and evaluation of benzimidazole-NsCOXis hybrids for the treatment of Alzheimer’s disease

  2021cites this paper
• Celecoxib in a Preclinical Model of Repetitive Mild Traumatic Brain Injury: Hippocampal Learning Deficits Persist with Inflammatory and Excitotoxic Neuroprotection

  2021cites this paper
• Is γ-secretase a beneficial inactivating enzyme of the toxic APP C-terminal fragment C99?

  2021cites this paper
• Sex and gender differences in Alzheimer’s disease: current challenges and implications for clinical practice

  2020cites this paper
• Alzheimer’s Disease: New Concepts on the Role of Autoimmunity and NLRP3 Inflammasome in the Pathogenesis of the Disease

  2020cites this paper
• The brain consequences of systemic inflammation were not fully alleviated by ibuprofen treatment in mice

  2020cites this paper
• Anti-inflammatories in Alzheimer’s disease—potential therapy or spurious correlate?

  2020cites this paper
• What works and what does not work in Alzheimer’s disease? From interventions on risk factors to anti‐amyloid trials

  2020cites this paper
• Tumor Necrosis Factor (TNF) blocking agents are associated with lower risk for Alzheimer’s disease in patients with rheumatoid arthritis and psoriasis

  2020cites this paper
• A Path Toward Precision Medicine for Neuroinflammatory Mechanisms in Alzheimer's Disease

  2020cites this paper
• Pharmacological approaches to mitigate neuroinflammation in Alzheimer's disease.

  2020cites this paper
• Modulation of Neuroin ammation by Low-dose Radiation Therapy in an Animal Model of Alzheimer’s Disease

  2020cites this paper
• Future Treatment of Alzheimer Disease

  2019cites this paper
• Inflammatory mechanisms in neurodegeneration

  2019cites this paper
• The Formyl Peptide Receptor 2 Regulates Microglial Phenotype Through Immunometabolism: Implications for Alzheimer’s Disease

  2019cites this paper
• Harnessing Immunoproteostasis to Treat Neurodegenerative Disorders.

  2019cites this paper
• Microwave-assisted synthesis and in vitro stability of N-benzylamide non-steroidal anti-inflammatory drug conjugates for CNS delivery.

  2019cites this paper
• Neuroimmune interactions in Alzheimer's disease-New frontier with old challenges?

  2019cites this paper
• The P2X7 receptor: a new therapeutic target in Alzheimer’s disease

  2019cites this paper
• Stem cell therapies for Alzheimer's disease: is it time?

  2019cites this paper
• Tumor Necrosis Factor (TNF) Blocking Agents are Associated with Lower Risk for Alzheimer’s Disease in Patients with Rheumatoid Arthritis and Psoriasis

  2019cites this paper
• Neuroprotective effect of diclofenac on chlorpromazine induced catalepsy in rats

  2019cites this paper
• 알츠하이머 치매 약물치료의 현황과 미래

  2018cites this paper
• Peptides as Potential Therapeutics for Alzheimer’s Disease

  2018cites this paper
• Celecoxib Prevents Cognitive Impairment and Neuroinflammation in Soluble Amyloid β-treated Rats.

  2018cites this paper
• An update on pathological implications of enzymatic dysregulation in Alzheimer's disease

  2018cites this paper
• Human Alzheimer’s disease gene expression signatures and immune profile in APP mouse models: a discrete transcriptomic view of Aβ plaque pathology

  2018cites this paper
• Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty

  2018cites this paper
• Cyclooxygenase-2 inhibitors as a therapeutic target in inflammatory diseases.

  2018cites this paper
• Integrated communications between cyclooxygenase‐2 and Alzheimer's disease

  2018cites this paper
• Innate immune activation in Alzheimer's disease.

  2018cites this paper
• Deficiency in the transcription factor NRF2 worsens inflammatory parameters in a mouse model with combined tauopathy and amyloidopathy

  2018cites this paper
• Inflammation and dementia: Using rheumatoid arthritis as a model to develop treatments?

  2018cites this paper
• Past and Future of Drug Treatments for Alzheimer's Disease

  2018cites this paper
• The borderland between normal aging and dementia

  2017cites this paper
• The use of non-steroidal anti-inflammatory drugs in neurological diseases.

  2017cites this paper
• Four Decades of Research in Alzheimer’s Disease (1975–2014): A Bibliometric and Scientometric Analysis

  2017cites this paper
• Alpha-2 macroglobulin in Alzheimer’s disease: a marker of neuronal injury through the RCAN1 pathway

  2017cites this paper
• Neuroinflammation, Alzheimer’s disease and periodontal disease: is there an association between the two processes?

  2017cites this paper
• Targeting neuroinflammation in Alzheimer’s disease: evidence for NSAIDs and novel therapeutics

  2017cites this paper
• Downregulation of miR‐7116‐5p in microglia by MPP+ sensitizes TNF‐α production to induce dopaminergic neuron damage

  2017cites this paper
• In silico-based screen synergistic drug combinations from herb medicines: a case using Cistanche tubulosa

  2017cites this paper
• Development of a core outcome set for disease modification trials in mild to moderate dementia: a systematic review, patient and public consultation and consensus recommendations.

  2017cites this paper
• Amelioration of amyloid-β-induced deficits by DcR3 in an Alzheimer’s disease model

  2017cites this paper
• Targeting Neuroinflammation to Treat Alzheimer’s Disease

  2017cites this paper
• Neuroinflammatory challenges compromise neuronal function in the aging brain: Postoperative cognitive delirium and Alzheimer's disease

  2017cites this paper
• PIPS one No Effect of One-Year Treatment with Indomethacin on Alzheimer ' s Disease Progression : A Randomized Controlled Trial

  2017cites this paper
• Featured Article Longitudinal decline in mild-to-moderate Alzheimer's disease: Analyses of placebo data from clinical trials

  2016cites this paper
• Beyond Cholinesterase Inhibition: Anti-Inflammatory Role and Pharmacological Profile of Current Drug Therapy for Alzheimer's Disease.

  2016cites this paper
• HISTOLOGICAL AND BEHAVIORAL CONSEQUENCES OF REPEATED MILD TRAUMATIC BRAIN INJURY IN MICE

  2016cites this paper
• Detection of Cyclooxygenase-1 in Activated Microglia During Amyloid Plaque Progression: PET Studies in Alzheimer’s Disease Model Mice

  2016cites this paper
• Pharmacotherapy of Dementia

  2016cites this paper
• Post Hoc Analyses of ApoE Genotype-Defined Subgroups in Clinical Trials

  2016cites this paper
• Astrocytes: a central element in neurological diseases

  2016cites this paper
• The contribution of neuroinflammation to amyloid toxicity in Alzheimer's disease

  2016cites this paper
• Targeting neuroinflammation in Alzheimer’s disease

  2016cites this paper
• Targeting innate immunity for neurodegenerative disorders of the central nervous system

  2016cites this paper
• Review Article Neuroinflammation in Alzheimer's disease: Current evidence and future directions

  2016cites this paper
• Longitudinal decline in mild‐to‐moderate Alzheimer's disease: Analyses of placebo data from clinical trials

  2016cites this paper
• The Rationale for Insulin Therapy in Alzheimer’s Disease

  2016cites this paper
• Franco Giubilei-CNS&ND-MS

  2016cites this paper
• Untangling the Web: Toxic and Protective Effects of Neuroinflammation and PGE2 Signaling in Alzheimer's Disease.

  2016cites this paper
• Fighting Chronic Neuroinflammation by Boosting Autoimmunity: The Distinction Between Neurodegenerative Diseases and Multiple Sclerosis

  2016cites this paper
• Neuroinflammation in Alzheimer's disease: Current evidence and future directions

  2016cites this paper
• Structural insight into the inhibition of carbonic anhydrase by the COX-2-selective inhibitor polmacoxib (CG100649).

  2016cites this paper
• Membrane Damage Induced by Amyloid Beta and a Potential Link with Neuroinflammation.

  2016cites this paper
• Neuroinflammation in Alzheimer's disease; A source of heterogeneity and target for personalized therapy.

  2015cites this paper
• Ibuprofen in Prevention of Neurodegenerative Diseases

  2015cites this paper
• Acta Neuropathologica Astrocytes: a central element in neurological diseases

  2015cites this paper
• Neuroinflammation in Alzheimer's disease.

  2015cites this paper
• Médicaments et cognition chez le sujet âgé

  2015cites this paper
• Eicosanoids Derived From Arachidonic Acid and Their Family Prostaglandins and Cyclooxygenase in Psychiatric Disorders

  2015cites this paper
• Modulation of Aβ42 in vivo by γ-secretase modulator in primates and humans

  2015cites this paper
• Resolution of inflammation as a therapeutic target for Alzheimer's disease

  2015cites this paper
• The Role of Inflammation in Alzheimer’s Disease

  2015cites this paper